Effects of IMC-A12 in Combination With High Intensity Chemotherapy

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma

What is the trial about?

To find out the effects of giving IMC-A12 in combination with high intensity chemotherapy.

Who can participate?

Patients diagnosed with high-risk rhabdomyosarcoma.

What is involved?

Length of study is 51 weeks. Standard cancer care.

Contact Nemours Clinical Trials

Trial Name: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma

COG#: ARST08P1

Contact Information

(800) 354-5690
clinicaltrials@nemours.org